Molecular Formula: C₁₈₄H₂₉₂N₅₄O₅₇S
Molecular Weight: 4113.6 g/mol
Sequence: Modified GLP-1 analog with DPP-4 resistance
Purity: >99% | Vial Size: 6mg | Storage: -20°C, protect from light
Product Overview
GLP1-R represents next-generation glucagon-like peptide-1 receptor agonist technology designed for comprehensive metabolic and multi-system research. This advanced synthetic peptide mimics endogenous GLP-1 hormone action while providing enhanced stability and extended half-life through DPP-4 enzyme resistance. Unlike natural GLP-1 with its 2-minute plasma half-life, GLP1-R offers sustained receptor activation enabling detailed investigation of GLP-1 pathway mechanisms across diverse physiological systems.
Revolutionary Incretin Mechanism
GLP1-R functions as a selective agonist for GLP-1 receptors found throughout the body, particularly in pancreatic islets, brain, cardiovascular tissue, and gastrointestinal tract. The peptide activates G protein-coupled receptor pathways, triggering glucose-dependent insulin secretion, glucagon suppression, delayed gastric emptying, and central appetite regulation. This multi-target approach provides researchers with tools to investigate complex metabolic interactions and therapeutic mechanisms.
Primary Research Applications
Diabetes & Metabolic Research
GLP1-R demonstrates exceptional glucose-lowering efficacy through glucose-dependent insulin stimulation from pancreatic β-cells. Studies show significant HbA1c reductions without hypoglycemia risk, making it invaluable for type 2 diabetes mechanism research. The peptide enhances β-cell proliferation while reducing apoptosis, offering insights into islet preservation strategies.
Obesity & Weight Management Studies
Clinical research reveals substantial weight loss effects through central appetite suppression and delayed gastric emptying. GLP1-R activates hypothalamic GLP-1 receptors, reducing food intake and promoting satiety. Studies demonstrate 10-15% body weight reductions, positioning it as a powerful tool for obesity mechanism investigations.
Cardiovascular Protection Research
Recent studies confirm significant cardiovascular benefits beyond metabolic effects. GLP1-R reduces major adverse cardiovascular events (MACE) by 13-26% in clinical trials. The peptide improves endothelial function, reduces blood pressure, enhances myocardial contractility, and provides cardioprotective effects during ischemic events through direct cardiac GLP-1 receptor activation.
Neuroprotection & Cognitive Studies
Emerging research demonstrates GLP1-R's ability to cross blood-brain barriers and activate CNS GLP-1 receptors. Studies show neuroprotective effects in Alzheimer's and Parkinson's disease models through reduced inflammation, enhanced neuronal survival, and improved cognitive function. The peptide stimulates hippocampal neurogenesis and synaptic plasticity.
Renal Protection Research
GLP1-R provides significant nephroprotective effects independent of glucose control. Studies demonstrate reduced albuminuria, preserved glomerular filtration rate, and decreased chronic kidney disease progression. The peptide reduces renal inflammation and fibrosis while improving endothelial function in kidney vasculature.
Non-Alcoholic Fatty Liver Disease (NAFLD)
Research demonstrates significant improvements in hepatic steatosis and inflammation markers. GLP1-R reduces liver fat content, improves hepatic insulin sensitivity, and decreases inflammatory cytokines. Studies show potential for treating NASH progression through direct hepatic GLP-1 receptor activation.
Mechanism of Action
Glucose Homeostasis: Enhances insulin secretion, suppresses glucagon release
Gastric Motility: Delays emptying, promotes satiety signals
Cardiovascular: Improves endothelial function, reduces inflammation
Neuroprotection: Activates survival pathways, reduces neuroinflammation
Renal Protection: Reduces albuminuria, preserves kidney function
Hepatic: Improves steatosis, reduces liver inflammation
Research Advantages
Extended Half-Life: Hours vs. minutes compared to native GLP-1
Multi-System Effects: Pancreatic, cardiovascular, neural, renal, hepatic applications
Glucose-Dependent Action: No hypoglycemia risk in normoglycemic conditions
Weight Loss Effects: Significant body weight reduction capabilities
Cardiovascular Benefits: Proven MACE reduction in clinical studies
Neuroprotective Properties: CNS penetration and cognitive benefits
Renal Protective: Independent nephroprotective mechanisms
Quality Specifications
Every GLP1-R batch undergoes comprehensive quality control:
HPLC purity analysis confirming >99% purity
Mass spectrometry molecular weight verification
DPP-4 resistance confirmation testing
Endotoxin testing (<1.0 EU/mg)
USP sterility testing standards
Bioactivity assays using GLP-1 receptor cell lines
Certificate of Analysis provided with shipment
Storage & Reconstitution
Store lyophilized powder at -20°C in sealed vials. Protect from light and humidity. Reconstitute with bacteriostatic water or sterile saline immediately before use. Once reconstituted, use within 24 hours or store at -80°C for short-term use. Avoid repeated freeze-thaw cycles to maintain receptor binding affinity.
Research Protocol Applications
Glucose homeostasis and diabetes mechanism studies
Weight management and appetite regulation research
Cardiovascular protection and MACE prevention studies
Neuroprotection and cognitive enhancement research
Chronic kidney disease progression studies
NAFLD/NASH mechanism investigations
Anti-inflammatory pathway research
Combination therapy optimization studies
Clinical Translation Potential
GLP1-R research applications span from basic mechanism studies to translational research for multiple therapeutic areas. The peptide's proven clinical efficacy across diabetes, obesity, and cardiovascular indications provides strong foundation for investigating novel therapeutic applications in neurodegeneration, kidney disease, and metabolic dysfunction.
Research Use Only: Not for human or veterinary therapeutic applications. Handle according to laboratory safety protocols and institutional research guidelines.